NEWS & EVENTS
Kitov Announces Consensi™ Commercialization Agreement for China
TEL AVIV, Israel | May 11, 2018 – Kitov Pharma Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a definitive license and commercialization agreement for the Chinese market, granting exclusive rights to import, manufacture and distribute its lead drug candidate, Consensi™, in China to Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharma), a Chinese public company traded on the Shenzhen Stock Exchange.
HC2 Announces Pansend Life Sciences Portfolio Company Benevir Biopharm to be Acquired by Janssen Biotech, Inc. for up to $1.04 Billion
New York | May 02, 2018 – HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).
BeneVir is a portfolio company within HC2’s Pansend Life Sciences (“Pansend”) subsidiary. Pansend is led by David A. Present M.D., Founder and General Partner, and Cherine Eldumiati Plumaker, Founder and General Partner. HC2 made its initial investment in BeneVir in 2014, and currently owns approximately 76 percent of the company’s equity.
Newly Approved Treatment for Impetigo to be Commercialized by Cutanea Life Sciences, Inc.
Exclusive US rights acquired by CLS | March 5, 2018 (WAYNE, PA) – Cutanea Life Sciences, Inc. has acquired the exclusive US commercialization rights for Xepi™ (ozenoxacin) Cream, 1% from Medimetriks Pharmaceuticals, Inc. Xepi™ is licensed from Spanish drug maker FERRER INTERNACIONAL, S.A., who developed the patented topical impetigo treatment that was recently approved for use in the U.S. by the Food and Drug Administration.